Literature DB >> 9063500

Microvascular degeneration in hereditary cystatin C amyloid angiopathy of the brain.

Z Z Wang1, O Jensson, L Thorsteinsson, H V Vinters.   

Abstract

Hereditary cystatin C amyloid angiopathy (HCCAA), an autosomal dominant form of cerebral amyloid angiopathy (CAA) occurring primarily in Iceland, is characterized by a variant cystatin C amyloid deposition in the walls of cerebral parenchymal and leptomeningeal vessels. Cystatin C is also found to colocalize with amyloid beta/A4 protein in cerebral vessel walls of patients with Alzheimer's disease (AD), sporadic CAA, and hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). The abundance of cystatin C deposition in cerebral blood vessel walls suggests that cellular elements of the vessel wall itself may play a role in its deposition. Microvascular changes in the brains of HCCAA patients were investigated by single- and double-label immunohistochemistry. We found that cystatin C amyloid immunoreactivity was present not only in cerebral cortical and leptomeningeal vessels, but also in white matter parenchymal vessels. Cystatin C deposition was more prominent in the media of parenchymal vessels and in the adventitia of leptomeningeal vessels. Smooth muscle (sm) cells were few or could not be identified within vessel walls showing extensive cystatin C deposition, suggesting progressive loss of these cells as cystatin C accumulates. However, in less severely affected vessels, cystatin C was present in cells that also had the phenotype of sm, suggesting that sm cells synthesize or process cystatin C. Cystatin C immunoreactivity was in addition, detected in some neuronal cell bodies throughout the cortex in patients with HCCAA and AD-related CAA. Our results indicate that cellular components of the vessel walls may play an important role in cystatin C deposition, as they do in beta/A4 deposition in AD-related CAA. Cystatin C deposition within the vascular media and adventitia, with associated vessel wall injury as manifested by sm cell loss, represents microvascular degeneration that leads to cerebral hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063500     DOI: 10.1111/j.1699-0463.1997.tb00538.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

1.  Pathological changes in basement membranes and dermal connective tissue of skin from patients with hereditary cystatin C amyloid angiopathy.

Authors:  Asbjorg Osk Snorradottir; Helgi J Isaksson; Saevar Ingthorsson; Elias Olafsson; Astridur Palsdottir; Birkir Thor Bragason
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

2.  Serum cystatin C and the risk of Alzheimer disease in elderly men.

Authors:  J Sundelöf; J Arnlöv; E Ingelsson; J Sundström; S Basu; B Zethelius; A Larsson; M C Irizarry; V Giedraitis; E Rönnemaa; M Degerman-Gunnarsson; B T Hyman; H Basun; L Kilander; L Lannfelt
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

3.  Cystatin C, a potential marker for cerebral microvascular compliance, is associated with white-matter hyperintensities progression.

Authors:  Woo-Jin Lee; Keun-Hwa Jung; Young Jin Ryu; Jeong-Min Kim; Soon-Tae Lee; Kon Chu; Manho Kim; Sang Kun Lee; Jae-Kyu Roh
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

Review 4.  The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy.

Authors:  Pablo Cisternas; Xavier Taylor; Cristian A Lasagna-Reeves
Journal:  Int J Mol Sci       Date:  2019-12-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.